设为首页收藏本站

中国病毒学论坛|我们一直在坚持!

 找回密码
 立即注册

QQ登录

只需一步,快速开始

搜索
热搜: 活动 交友 discuz
查看: 1334|回复: 0
打印 上一主题 下一主题

CUL5-Mediated APOBEC3G Degradation in HIV Infection

[复制链接]

2205

帖子

2852

学分

3万

金币

管理员

Rank: 9Rank: 9Rank: 9Rank: 9

积分
2852
跳转到指定楼层
楼主
发表于 2019-7-24 13:34:27 | 只看该作者 回帖奖励 |倒序浏览 |阅读模式
ARIH2 Is a Vif-Dependent Regulator of CUL5-Mediated APOBEC3G Degradation in HIV Infection
Ruth Hüttenhain
Jiewei Xu
Lily A. Burton
David E. Gordon
Judd F. Hultquist
Jeffrey R. Johnson
Laura Satkamp
Joseph Hiatt
David Y. Rhee
Kheewoong Baek
David C. Crosby
Alan D. Frankel
Alexander Marson
J. Wade Harper
Arno F. Alpi
Brenda A. Schulman
John D. Gross
Nevan J. Krogan 14

Published:June 25, 2019
DOI:https://doi.org/10.1016/j.chom.2019.05.008


Summary
The Cullin-RING E3 ligase (CRL) family is commonly hijacked by pathogens to redirect the host ubiquitin proteasome machinery to specific targets. During HIV infection, CRL5 is hijacked by HIV Vif to target viral restriction factors of the APOBEC3 family for ubiquitination and degradation. Here, using a quantitative proteomics approach, we identify the E3 ligase ARIH2 as a regulator of CRL5-mediated APOBEC3 degradation. The CUL5 Vif/CBFß complex recruits ARIH2 where it acts to transfer ubiquitin directly to the APOBEC3 targets. ARIH2 is essential for CRL5-dependent HIV infectivity in primary CD4 + T cells. Furthermore, we show that ARIH2 cooperates with CRL5 to prime other cellular substrates for polyubiquitination, suggesting this may represent a general mechanism beyond HIV infection and APOBEC3 degradation. Taken together, these data identify ARIH2 as a co-factor in the Vif-hijacked CRL5 complex that contributes to HIV infectivity and demonstrate the operation of the E1-E2-E3/E3-substrate ubiquitination mechanism in a viral infection context.


分享到:  QQ好友和群QQ好友和群 QQ空间QQ空间 腾讯微博腾讯微博 腾讯朋友腾讯朋友
收藏收藏 分享分享 支持支持 反对反对
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

QQ|论坛App下载|Archiver|小黑屋|中国病毒学论坛    

GMT+8, 2024-11-26 04:39 , Processed in 0.087193 second(s), 29 queries .

Powered by Discuz! X3.2

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表